Societal impact assessment

Abundance Potential

A new sorting method opens up Salmonella’s hidden compartment

Assessment takeaway

Unknown · insufficient evidence

PhagoCyt shows meaningful but bounded potential to improve research on Salmonella-containing phagosomes. Its broader societal benefit remains speculative because the supplied evidence is from laboratory models and does not establish clinical outcomes or wider access (evidence-2341, evidence-2342, evidence-2345).

AI-generated · Not editor reviewedAssessed 2026-11-16Rubric abundance-potential-v1

This describes conditional potential, not a probability or measured outcome. Unknown values are not zero, and harms are not subtracted from the total.

Assessment scope

Development
PhagoCyt, a flow-sorting method for isolating Salmonella-containing phagosomes for joint host and bacterial protein analysis.
Baseline
Existing pathogen-containing phagosome isolation approaches, including ultracentrifugation-based methods.
Population
Biomedical researchers studying Salmonella-host interactions as direct users; people affected by Salmonella infection are only possible indirect beneficiaries if later research leads to useful interventions.
Geography
Potentially global research settings; the supplied evidence is limited to laboratory models and does not establish geographic adoption or reach.
Target assumptions
The method can be independently reproduced and used in other relevant models; research labs can access the required flow cytometry and mass spectrometry; and any future health benefit depends on downstream validation and translation.

Five dimensions

Human wellbeing
Unknown · The supplied evidence reports laboratory infection and survival experiments, not patient health outcomes or a demonstrated intervention. Sources: evidence-2342, evidence-2344
Affordability and access
1/4 · Fewer required cells and higher throughput than previous techniques could modestly lower research barriers for labs that already have suitable instruments. The evidence does not establish costs, equipment availability, or broader access. Sources: evidence-2345
Reach and fairness
Unknown · The supplied evidence does not show who can access or use the method across institutions, regions, or affected populations. Sources: evidence-2341, evidence-2345
Environment and resources
Unknown · The supplied evidence does not assess environmental effects or resource use beyond the reported cell-input comparison. Sources: evidence-2345
Scientific capability
2/4 · The method enables analysis of host and bacterial proteins in isolated, intact Salmonella-containing phagosomes, with reported purity above 95% and advantages over prior techniques. This is a meaningful research capability, bounded by the tested models and infection conditions. Sources: evidence-2341, evidence-2345

Evidence, confidence and timing

Evidence maturity

Finding: Laboratory. The method was tested in infected THP-1-derived macrophages, with follow-up candidate-gene experiments in mouse-derived macrophages; the evidence remains within laboratory models. The supplied source excerpt identifies the article as an uncorrected proof.

Societal benefit: Early speculative. The reported findings may guide future work on host defenses and bacterial survival, but the supplied evidence does not demonstrate improved prevention, diagnosis, or treatment.

Confidence: Moderate. The supplied claims describe specific method validation and experiments from a peer-reviewed study, but confidence is limited by the narrow laboratory scope, the source excerpt's uncorrected-proof label, and the absence of independent replication in the packet.

Conditional time horizon: Unknown. The supplied evidence gives no schedule for wider adoption or for translating the research findings into health benefits.

Possible benefits

  • Higher-purity phagosome isolation, lower cell requirements, and higher throughput could help researchers examine host and bacterial proteins in the same intracellular niche. Sources: evidence-2341, evidence-2345
  • The observed mitochondrial and bacterial-protein patterns may guide follow-up research into host defenses and bacterial survival, with any health benefit depending on later validation and translation. Sources: evidence-2342, evidence-2344

Risks and possible harms

  • Researchers could overinterpret tentative mechanisms: the evidence does not establish how mitochondrial material reaches phagosomes or how much it contributes to bacterial killing; candidate bacterial proteins are not all confirmed effectors. Affected groups: Researchers and, if preliminary findings are translated prematurely, people affected by Salmonella infection. Sources: evidence-2342, evidence-2344

Distribution and adoption

Who might be excluded

  • Patients, clinical settings, and populations beyond the tested macrophage models are not represented in the reported validation. Sources: evidence-2341, evidence-2344

Adoption barriers

  • Use depends on access to flow-sorting and sensitive mass-spectrometry capabilities; the supplied evidence does not quantify costs or access to this equipment. Sources: evidence-2341, evidence-2345

Assumptions and conditions that could change the assessment

  • The reported sorting performance and protein findings will reproduce across independent labs and relevant models beyond the conditions tested. Sources: evidence-2341, evidence-2343
  • Later research will turn improved understanding of host-pathogen interactions into useful health interventions; this outcome is not demonstrated by the supplied study. Sources: evidence-2342, evidence-2344
  • Independent replication across additional strains and relevant cell models, plus comparative evidence on costs and equipment access, could change the capability and access assessments. Sources: evidence-2341, evidence-2344, evidence-2345
  • Demonstrated patient benefit or measured environmental and resource effects would provide evidence for currently unknown dimensions. Sources: evidence-2342, evidence-2344, evidence-2345

Citations

  1. evidence-2341 · PhagoCyt enables isolation of Salmonella-containing phagosomes and mapping of host and bacteria remodelling of the intracellular niche · R; i; t; i; k; a; ; C; h; a; t; t; e; r; j; e; e · 10.1371/journal.pbio.3004073 · Captured publisher article text · Open source
  2. evidence-2342 · PhagoCyt enables isolation of Salmonella-containing phagosomes and mapping of host and bacteria remodelling of the intracellular niche · R; i; t; i; k; a; ; C; h; a; t; t; e; r; j; e; e · 10.1371/journal.pbio.3004073 · Captured publisher article text · Open source
  3. evidence-2343 · PhagoCyt enables isolation of Salmonella-containing phagosomes and mapping of host and bacteria remodelling of the intracellular niche · R; i; t; i; k; a; ; C; h; a; t; t; e; r; j; e; e · 10.1371/journal.pbio.3004073 · Captured publisher article text · Open source
  4. evidence-2344 · PhagoCyt enables isolation of Salmonella-containing phagosomes and mapping of host and bacteria remodelling of the intracellular niche · R; i; t; i; k; a; ; C; h; a; t; t; e; r; j; e; e · 10.1371/journal.pbio.3004073 · Captured publisher article text · Open source
  5. evidence-2345 · PhagoCyt enables isolation of Salmonella-containing phagosomes and mapping of host and bacteria remodelling of the intracellular niche · R; i; t; i; k; a; ; C; h; a; t; t; e; r; j; e; e · 10.1371/journal.pbio.3004073 · Captured publisher article text · Open source